LumiraDx
221 Crescent St
5th Floor
Waltham
Massachusetts
02453
United States
Website: http://www.lumiradx.com/
Email: recruitment@lumiradx.com
About LumiraDx
LumiraDx is transforming community-based healthcare by providing fast, accurate and comprehensive diagnostic information at the point of need. The company’s innovative LumiraDx Platform is designed to perform a broad menu of tests including infectious and cardiovascular disease, diabetes and coagulation disorders, and deliver lab-comparable performance with results in 12 minutes. With its point of care platform, and Fast Lab Solutions, LumiraDx’s testing options support the diagnostic needs across settings;from the lab, to hospitals, the physician’s office, the workplace, and schools. Founded in 2014, LumiraDx is based in the UK with R&D and manufacturing sites across the US and Europe.
Stock Symbol: LMDX
Stock Exchange: NASDAQ
LumiraDx transforming healthcare at the point of need
18 articles with LumiraDx
-
LumiraDx Reports Second Quarter 2022 ResultsStrong Pipeline Progress and Commercialization Priorities for Newly Authorized Products
8/18/2022
LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced operational and financial results for the second quarter ended June 30, 2022.
-
LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 18
8/11/2022
LumiraDx Limited (Nasdaq: LMDX ), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 18th, 2022.
-
LumiraDx Announces Pricing of Public Offering of Common Shares and Concurrent Private Placement
7/21/2022
LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced the pricing of its underwritten public offering of 43,000,000 common shares at a price to the public of $1.75 per share.
-
LumiraDx Announces Proposed Public Offering of Common Shares
7/19/2022
LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced that it has commenced an underwritten public offering of 40,000,000 common shares.
-
LumiraDx Receives CE Mark for Two Multiplex Tests: LumiraDx Dual-Target SARS-CoV-2 STAR Complete and LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete
6/8/2022
LumiraDx Limited announced that it has achieved CE Mark for two new Fast Lab Solutions molecular tests, including Dual-Target SARS-CoV-2 STAR Complete and SARS-CoV-2 & Flu A/B RNA STAR Complete.
-
LumiraDx Expands its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test
6/2/2022
LumiraDx Limited announced it has expanded its cardiovascular offering with a CE Mark for its new NT-proBNP test to aid in the diagnosis of CHF and an updated CE Mark for its D-Dimer test to now rule out venous thromboembolism in symptomatic patients.
-
LumiraDx HbA1c Test Achieves CE Mark, Addresses Growing Global Need for Diabetes Screening and Monitoring with its Next-Generation Point of Care Diagnostic Platform
5/26/2022
LumiraDx Limited, a next-generation point of care diagnostics company, announced its HbA1c test has achieved CE Marking.
-
LumiraDx Receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test
5/20/2022
LumiraDx Limited, a next-generation point of care diagnostics company, announced that its rapid COVID-19 antigen assay, LumiraDx SARS-CoV-2 Ag Test has successfully received the Emergency Use Listing by the World Health Organization in their latest response effort to combat COVID-19.
-
LumiraDx Five-Minute SARS-CoV-2 Ag Ultra Test Achieves CE Marking
5/19/2022
LumiraDx Limited, a next-generation point of care diagnostics company, announced its SARS-CoV-2 Ag Ultra Test achieved CE Marking.
-
LumiraDx Reports First Quarter 2022 Results
5/11/2022
LumiraDx Limited, a next-generation point of care diagnostics company, announced financial and operational results for the first quarter ended March 31, 2022.
-
LumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 11
4/29/2022
LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its first quarter financial results on Wednesday, May 11, 2022.
-
LumiraDx Reports Fourth Quarter and Full Year 2021 Results
3/10/2022
LumiraDx Limited, a next-generation point of care diagnostics company, announced financial and operational results for the fourth quarter and full year ended December 31, 2021.
-
LumiraDx Announces Pricing of $56.5 Million Convertible Notes Offering
3/1/2022
LumiraDx Limited announced that it entered into privately negotiated subscription agreements with certain investors pursuant to which LumiraDx agreed to sell and the investors agreed to purchase from LumiraDx $56.5 million aggregate principal amount of 6.00% Convertible Senior Subordinated Notes due 2027.
-
LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant
1/14/2022
Results from ongoing testing and monitoring of COVID-19 variants shows the rapid microfluidic test detects Omicron at a comparable sensitivity to other variants.
-
LumiraDx CRP Test Achieves CE Marking
1/11/2022
LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced its C-reactive protein (CRP) Test has achieved CE Marking.
-
LumiraDx has Commenced Shipments in Europe for its COVID-19 & Flu A/B Microfluidic Antigen Test
1/11/2022
LumiraDx, a next-generation point of care diagnostics company, announced preliminary results for the fourth quarter of 2021 as well as expected full-year revenue.
-
LumiraDx COVID-19 & Flu A/B Rapid Antigen Test Achieves CE Marking
12/23/2021
LumiraDx, a next-generation point of care diagnostics company, announced its SARS-CoV-2 & Flu A/B Antigen Test has achieved CE Marking.
-
LumiraDx Fast Lab Solutions Partners with Audere for At-Home Self- Collection Solution for use with SARS-CoV-2 RNA STAR Complete
12/15/2021
LumiraDx (Nasdaq: LMDX) today announced a partnership with digital health non-profit Audere, to offer a self-collected COVID-19 nasal specimen collection kit that has been authorized for use with the LumiraDx SARS-CoV-2 RNA STAR Complete assay to process self-collected samples.